|New Medicines For Tuberculosis
Press release 19 th March 2009
Benzothiazinones Kill Mycobacterium tuberculosis by Blocking Arabinan Synthesis Science. ISSN 0036-8075 (print), 1095-9203 (online)
Scientific Meeting, Kamila Hotel, Bratislava, Slovakia
22 nd - 23 rd May 2006
Scientific Meeting, Linnean Society, London, England
22 nd - 23 rd June 2009
Project number: 018923
New Medicines for Tuberculosis (NM4TB) aims to successfully develop new drugs for the treatment of tuberculosis (TB) through an integrated approach implemented by a team that combines some of Europe's leading academic TB researchers with a major pharmaceutical company and three SMEs, all with a strong commitment to discovering new anti-infective agents. NM4TB has a comprehensive portfolio of potential and validated targets plus several novel, proprietary anti-TB agents in its drug development pipeline. Among the validated targets are several enzymes involved in highly druggable areas such as cell wall biogenesis, nucleic acid synthesis and central metabolic pathways for which assays amenable to high-throughput screening are available. Intensive efforts will focus on rapidly emerging targets that impact upon two as-yet untouched areas of the physiology of Mycobacterium tuberculosis signal transduction pathways and persistence.Background
Tuberculosis (TB) is one of the oldest diseases known to man and has infected one third of the world's population. As a result, someone dies from the disease every 15 seconds and 30 million more people will lose their lives to TB in the next decade. Although directly observed short course chemotherapy is available to treat the disease, this treatment is old, slow and inefficient by the current standards of the pharmaceutical industry. Here, we will employ the most innovative approaches to identify and validate targets for new drugs, and implement the screening and medicinal chemistry processes required to identify lead compounds for the generation of candidate drugs.Aim
To successfully develop new drugs for the treatment of tuberculosis (TB) with the following desired properties:
1) Development and implementation of novel enabling technologies required for drug development.
The proposed research will result in:
Mycobacterium tuberculosis, multidrug resistant TB, drug development, signal transduction pathways
If you have any problems, remarks or questions concerning this Web page, please write to email@example.com.